Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus
European Thyroid Journal · 01.08.2025 · 14 (4)
DOI: 10.1530/etj-25-0024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Thyroid Journal, online erschienen am 18.06.2025. Verfasst von Aleš Ryška und 15 weiteren Autor:innen. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Thyroid Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
As new precision oncology therapies become available in the thyroid cancer (TC) treatment landscape, appropriate and timely biomarker testing is crucial for treatment selection and requires a multidisciplinary approach. Recently published European guidelines on advanced/metastatic TC management include a special focus on biomarker testing. However, to date, there remains a need for comprehensive European guidance for standardized molecular testing strategies in TC that encompass a broad set of targetable or potentially targetable alterations, timing of testing, and patients to be tested. This expert opinion article outlines consensus testing algorithms for differentiated TC, medullary TC, and anaplastic TC from a team of endocrinologists, oncologists, molecular biologists, and pathologists to provide standardized recommendations for physicians involved in treating patients with advanced TC. In the differentiated TC algorithm, patients recommended for comprehensive testing by DNA and RNA next-generation sequencing (NGS) include those whose disease has progressed on or is resistant to radioactive iodine treatment. The medullary TC algorithm recommends RET germline testing for all patients at diagnosis. For patients exhibiting high-risk clinical or pathological features and those whose disease progresses, somatic RET testing with NGS should be discussed and conducted before considering systemic treatment. As anaplastic TC is a highly aggressive disease, molecular reflex testing for BRAF mutations is recommended for all patients at diagnosis, followed by DNA and RNA NGS for those who test BRAF negative. The article also provides consensus recommendations on the use of tumor tissue for testing and on centralization of molecular testing involving multidisciplinary tumor boards.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Julien Hadoux, Laura D Locati, Laura Fugazzola
Zitieren
APA
Ryška, A., Capdevila, J., Dettmer, M. S., Elisei, R., Führer, D., Hadoux, J., Jarząb, B., Locati, L. D., Newbold, K., Tallini, G., Uccella, S., Wirth, L., Singh, R., Simon, I. M., Camacho, P., & Fugazzola, L. (2025). Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus. European Thyroid Journal, 14(4). https://doi.org/10.1530/etj-25-0024
Vancouver
Ryška A, Capdevila J, Dettmer MS, Elisei R, Führer D, Hadoux J, et al. Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus. European Thyroid Journal. 2025;14(4). doi:10.1530/etj-25-0024
BibTeX
@article{Ryka2025,
author = {Ryška, Aleš and Capdevila, Jaume and Dettmer, Matthias S and Elisei, Rossella and Führer, Dagmar and Hadoux, Julien and Jarząb, Barbara and Locati, Laura D and Newbold, Kate and Tallini, Giovanni and Uccella, Silvia and Wirth, Lori and Singh, Ravinder and Simon, Iris M and Camacho, Pilar and Fugazzola, Laura},
title = {Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus},
journal = {European Thyroid Journal},
year = {2025},
volume = {14},
number = {4},
doi = {10.1530/etj-25-0024}
}
EUVIMED